Form 4 for HUMA Humacyte, Inc.
Accepted 2022-09-19 00:00:00 ET · period of report 2022-09-15 · accession 0001818382-22-000161 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-09-19 | 2022-09-15 | HUMA | Niklason Laura E | Pres, CEO, Dir, 10% | S - Sale | $4.00 | -1.52M | 18.93M | -7% | -$6.09M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-15 | S | D | 1,522,500 | $4.00 | 18,930,004 | I By Ayabudge LLC | — | — | (F1) This sale was made by an entity controlled by the spouse of Laura Niklason, the Reporting Person. This sale was done as a block trade to an existing investor of Humacyte, Inc. Laura Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly owned by Laura Niklason were sold in this transaction. |